Article
Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
Bone marrow transplantation - 1 Jan 1995
Scheffold C, Brandt K, Johnston V, Lefterova P, Degen B, Schöntube M, Huhn D, Neubauer A, Schmidt-Wolf I G
Abstract excerpt
Relapse is a major concern in autologous bone marrow transplantation (BMT). Therefore, purging of bone marrow to reduce the amount of tumor cells reinfused into the patient is widely used. Immunologic effector cells such as lymphokine activated killer (LAK) cells are attractive for purging of bone marrow since these cells might have an additional in vivo effect on tumor cells in contrast to other purging...
Topics
- Base Sequence
- Bone Marrow Purging
- Flow Cytometry
- Fluorescent Antibody Technique
- Humans
- Killer Cells, Lymphokine-Activated
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Molecular Sequence Data
- Phenotype
- RNA